Sermorelin

Sermorelin (GRF 1-29) is a synthetic 29-amino acid peptide representing the bioactive N-terminus of human GHRH. This is the minimum sequence retaining full activity of the natural hypothalamic hormone. Developed by Roger Guillemin (Nobel laureate, 1977) at the Salk Institute. Under the trade name Geref it was FDA-approved in 1997 for diagnosis and treatment of growth hormone deficiency in childhood; the branded form was discontinued for commercial reasons in 2008, but the generic version remains available in research grade. Classic "GHRH analog" — stimulates the pituitary to release endogenous GH in natural pulses, preserving physiological feedback. In modern anti-aging and biohacker literature it is often combined with GHRP (Ipamorelin or GHRP-2) for synergistic effect — the two mechanisms (GHRH + ghrelin pathway) potentiate each other. Half-life is short (~12 minutes), mimicking natural GH pulsation. Storage: -20°C lyophilized; reconstituted — 14 days at 2-8°C.